Product Regulation remains a hot topic, and this last year has seen protracted consultation between IRDA and the industry on the way forward. We shall consider the proposed regulations, and the problems they are designed to fix.
In December 2011, IRDA set up a Committee on Road map for Risk Based Solvency Approach in Insurance Sector. We shall have one of the members of this Committee to share its thoughts with us.
This last year has also seen the issuance or the development prior to issuance, of various Guidance Notes. We shall focus on two in particular:
1. GN10, which addresses the embedded value disclosures required of a company when it seeks a s listing. These metrics are interesting in themselves from a purely technical perspective, but, given their public disclosure, could also have an effect on companies' business plans and operating models. 2. GN6 (draft) which addresses certain aspects of the management, in particular the calculation of asset shares, of a participating fund. Given the focus on asset shares in recent draft regulation, and on the management of participating business in general, this session promises to promises to shed light on a number of pertinent topics.
Reinsurance regulation has also been subjected to regulatory scrutiny. We shall have a critical analysis of the proposed regulations and some speculation as to their likely effects.
Life insurance actuaries around the globe have been tracking mortality rates for centuries. As markets become more competitive, these studies become very important for pricing and valuation actuaries. In the most competitive markets the rate of change of the mortality rates is analysed in great detail and used to make projections. The lessons learned from countries like Russia, Canada and Sweden can be insightful for India. Lesson one: start collecting data early. Lesson two: actuaries have quite consistently under-estimate life expectancies.
Now that companies are required to report on their ALM positions to IRDA, we shall have an international overview of what regulators require of ALM, and how it may be used to assess a company's capital requirements.
The Current Issues in Life Assurance (CILA) Seminar is held annually by the Institute of Actuaries of India. Each issue being discussed this year is important in its own right and would make for interesting debate and insightful discussion. We look forward to meeting you at the 8th CILA on 29th and 30th November in Mumbai.
Speakers:
The speakers include stalwarts from the life assurance business and experts on the business from leading consulting companies. 
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Sanket Kawatkar Practice Leader (Life Insurance), Milliman India
He is the head of Milliman life insurance consulting practice in India and is based in Mumbai. He has been a consultant for over ten years and is well known in the industry. Prior to Milliman, Sanket worked with Watson Wyatt (now Towers Watson) for more than eight years and was responsible for the growth of its life insurance consulting practice in India. Sanket has also worked with the AIG group in Singapore and in India for over six years. His experience in AIG covered the roles of the actuary for the company's life insurance venture in India in its initial years, as well as that of a member of the actuarial team in Singapore, involved in product development and pricing, statutory valuations and experience analysis. 
Subha Neelakantan Country Manager -Gen Re Mumbai
Subha Neelakantan is the Country Manager of Gen Re Mumbai Liaison Office for the Life/Health business in India. She is a qualified actuary from the Institute of Actuaries of India. She has over 13 years experience. She has been with Gen Re for more than 4.5 years. At Gen Re Mumbai she is responsible for client relationships and various business activities. Prior to joining Gen Re, she worked with TATA AIG Life Insurance for over 7.5 years in various roles starting from product pricing, valuations to embedded value reporting. She is also a member of the Micro insurance advisory group.
